Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease.

Literature DB >> 10102447

Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease.

T J Montine¹, M F Beal, D Robertson, M E Cudkowicz, I Biaggioni, H O'Donnell, W E Zackert, L J Roberts, J D Morrow.

Abstract

Entities: Chemical Disease

Keywords: Non-programmatic

Mesh：

Substances：
Dinoprost

Year: 1999 PMID： 10102447 DOI： 10.1212/wnl.52.5.1104

Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910

Keyword Cloud
Cited

× No keyword cloud information.

28 in total

1. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration.

Authors: Erik S Musiek; Rebecca S Breeding; Ginger L Milne; Giuseppe Zanoni; Jason D Morrow; Bethann McLaughlin
Journal: J Neurochem Date: 2006-04-21 Impact factor: 5.372

Review 2. Antioxidants in Huntington's disease.

Authors: Ashu Johri; M Flint Beal
Journal: Biochim Biophys Acta Date: 2011-11-23

3. Reactive gamma-ketoaldehydes formed via the isoprostane pathway disrupt mitochondrial respiration and calcium homeostasis.

Authors: Irina G Stavrovskaya; Sergei V Baranov; Xiaofeng Guo; Sean S Davies; L Jackson Roberts; Bruce S Kristal
Journal: Free Radic Biol Med Date: 2010-06-02 Impact factor: 7.376

4. Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity.

Authors: Sean S Davies; Eric J Brantley; Paul A Voziyan; Venkataraman Amarnath; Irene Zagol-Ikapitte; Olivier Boutaud; Billy G Hudson; John A Oates; L Jackson Roberts
Journal: Biochemistry Date: 2006-12-06 Impact factor: 3.162

5. Prospects for redox-based therapy in neurodegenerative diseases.

Authors: A L Friedlich; M F Beal
Journal: Neurotox Res Date: 2000 Impact factor: 3.911

6. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

Authors: Cliona Stack; Daniel Ho; Elizabeth Wille; Noel Y Calingasan; Charlotte Williams; Karen Liby; Michael Sporn; Magali Dumont; M Flint Beal
Journal: Free Radic Biol Med Date: 2010-03-23 Impact factor: 7.376

Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease.

1. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration.

Review 2. Antioxidants in Huntington's disease.

3. Reactive gamma-ketoaldehydes formed via the isoprostane pathway disrupt mitochondrial respiration and calcium homeostasis.

4. Pyridoxamine analogues scavenge lipid-derived gamma-ketoaldehydes and protect against H2O2-mediated cytotoxicity.

5. Prospects for redox-based therapy in neurodegenerative diseases.

6. Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease.

Review 7. Markers of oxidant stress that are clinically relevant in aging and age-related disease.

Review 8. Inflammatory mediators as biomarkers in brain disorders.

Review 9. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models.

10. Increased isolevuglandin-modified proteins in glaucomatous astrocytes.